Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
10.34
+0.18 (1.77%)
At close: Dec 5, 2025, 4:00 PM EST
10.32
-0.02 (-0.19%)
After-hours: Dec 5, 2025, 5:01 PM EST
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Entrada Therapeutics stock has a target of 20, which predicts an increase of 93.42% from the current stock price of 10.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Entrada Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +93.42% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +93.42% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +93.42% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +93.42% | Feb 4, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +180.46% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
33.26M
from 210.78M
Decreased by -84.22%
Revenue Next Year
34.31M
from 33.26M
Increased by 3.16%
EPS This Year
-3.68
from 1.68
EPS Next Year
-4.21
from -3.68
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 63.0M | 63.0M | ||||
| Avg | 33.3M | 34.3M | ||||
| Low | 23.6M | 14.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -70.1% | 89.4% | ||||
| Avg | -84.2% | 3.2% | ||||
| Low | -88.8% | -55.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.63 | -3.18 | |
| Avg | -3.68 | -4.21 | |
| Low | -3.60 | -4.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.